- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01969019
A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy
A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Ning Guang, Professor
- Phone Number: 665344 (8621)64370045
- Email: guangning@medmail.com.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Recruiting
- Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital
-
Contact:
- Wei Zhu, Attending
- Phone Number: 602105 (8621)64370045
- Email: juvey1515@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients should meet the criteria of either a or b and together with c, d and e to include into the study.
a. Lid retraction with any one of the following: i) Thyroid dysfunction ii) Proptosis iii) Optic nerve involvement iv) Extraocular muscle involvement b. Thyroid dysfunction with any one of the following: i) Proptosis ii) Optic nerve involvement iii) Extraocular muscle involvement c. Exclude cases with such ophthalmological signs caused by other diseases. d. Moderate to severe patients defined by EUGOGO. e. Clinical activity score (CAS)≥3/7 f. Normal function of heart, liver and kidney.
Exclusion Criteria:
- Orbital decompression surgery needed immediately
- History of chronic recurrent or active infection
- History of peptic ulcer
- Patients with a history of chronic liver disease or liver disorders; ALT or AST above 2.5 times upper limit of normal
- History of HIV, hepatitis C or hepatitis B Positive
- Cardiovascular or cerebrovascular disease clinically significant
- Uncontrolled diabetes mellitus
- Use of corticosteroids during 12 weeks before to inclusion period
- Pregnant patient or patient who is planning to become pregnant during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: methylprednisolone
intravenous MP: 0.5g weekly for six weeks followed by 0.25g weekly for six weeks
|
|
Active Comparator: methylprednisolone plus prednisone
intravenous MP 0.5g daily for three days per week, twice, followed by 0.25g daily for three days per week, twice, and followed by tapering oral prednisone (starting with 60mg/d, then10 mg less/week than each previous week for the next 3 weeks, then20mg/week at the 5th week followed with 5mg less/week than each previous week for the next 3 weeks)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
response rate
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change of CAS, adverse effects and retreat
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Genetic Diseases, Inborn
- Thyroid Diseases
- Eye Diseases, Hereditary
- Graves Disease
- Exophthalmos
- Orbital Diseases
- Goiter
- Hyperthyroidism
- Eye Diseases
- Graves Ophthalmopathy
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
- Prednisone
Other Study ID Numbers
- CCEMD015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graves' Ophthalmopathy
-
Medical University of ViennaUnknownGraves Ophthalmopathy | Graves Disease | Graves' Ophthalmopathy WorsenedAustria
-
University of Sao PauloCompletedGraves' Ophthalmopathy | Graves' DiseaseBrazil
-
Odense University HospitalCompletedThyroid Associated Ophthalmopathy | Graves´ DiseaseDenmark
-
Sun Yat-sen UniversityRecruitingImmune System Diseases | Autoimmune Diseases | Endocrine System Diseases | Thyroid Diseases | Eye Diseases, Hereditary | Graves Ophthalmopathy | Graves Disease | Hyperthyroidism | Thyroid-associated OphthalmopathyChina
-
Ankara UniversityUnknownGraves' OphthalmopathyTurkey
-
Yonsei UniversityUnknownMild Graves' OphthalmopathyKorea, Republic of
-
Sun Yat-sen UniversityUnknownGraves' OphthalmopathyChina
-
National Taiwan University HospitalUnknownGraves' OphthalmopathyTaiwan
-
Silkiss, Rona Z., M.D., FACSLauer, Simeon, M.D.; Reier, Alice M.D.; Coleman, Morton M.D.CompletedThyroid Related Orbitopathy | Graves' Dysthyroid OphthalmopathyUnited States
-
Immunovant Sciences GmbHTerminatedGraves' Ophthalmopathy (GO)United States, Germany, Spain, Canada, Italy
Clinical Trials on methylprednisolone, prednisone
-
Bristol-Myers SquibbWithdrawnMelanoma | Renal Cell Carcinoma | Lung CancerUnited States
-
Nanjing University School of MedicineCompleted
-
Medical University of LodzRecruitingGlomerular DiseasePoland
-
University of California, San FranciscoMedical University of South Carolina; M.D. Anderson Cancer Center; University... and other collaboratorsEnrolling by invitationArterial Ischemic Stroke | Pediatric Stroke | ArteriopathyUnited States
-
Incyte CorporationCompletedGraft-versus-host Disease (GVHD)United States
-
Eye & ENT Hospital of Fudan UniversityUnknownSudden Hearing Loss | Vestibular VertigoChina
-
Massachusetts Eye and Ear InfirmaryNational Institute on Deafness and Other Communication Disorders (NIDCD)Completed
-
CelgeneCompletedSarcoidosis, PulmonaryUnited States, United Kingdom, Netherlands
-
Incyte CorporationCompletedGraft-versus-host Disease (GVHD)United States
-
Rutgers, The State University of New JerseyTerminated